Edgewise Therapeutics Inc recorded a cumulative net loss of $-197 million during 12 month ending in the second quarter 2026. The Healthcare sector has seen employees of 252 other companies achieving higher income per employee. While Edgewise Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3789 to 3817.
Edgewise Therapeutics Reports Promising Advancements Across Diverse Muscle and Cardiac Conditions Boulder, Colo. Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a pioneering biopharmaceutical firm specializing in muscle diseases, recently disclosed encouraging topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy (BMD). This advancement marks a significant achievement in their ongoing efforts to address muscular and cardiomyopathic diseases. The company also initiated the Phase 2 CIRRUS-HCM trial of EDG-7500, targeting obstructive hypertrophic cardiomyopathy (HCM), asserting its dedication to pioneering innovative therapeutic solutions. Phase 2 CANYON Trial Results: Progress in Becker Muscular Dystrophy Sevasemten, Edgewise s orally administered fast skeletal myosin inhibitor, demonstrated positive outcomes in the Phase 2 CANYON trial. The drug is engineered to protect muscle against contraction-induced damage, a significant concern in muscular dystrophies like BMD. The trial met its primary endpoint, showing a notable change from baseline in creatine kinase (CK) levels, a biomarker of muscle damage. Sevasemten represents a novel therapeutic approach that could transform the treatment landscape for individuals with BMD, offering hope for enhanced muscle protection and overall quality of life.
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock BOULDER, Colo. - Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, has revealed the pricing details for its underwritten offering of common stock. The company announced that it will be offering 21,818,182 shares at a price of $11.00 per share. Edgewise expects to generate gross proceeds of approximately $240 million from this offering, before deducting underwriting discounts, commissions, and offering expenses. The closing of the offering is set to take place on January 23. This announcement comes at a pivotal moment for Edgewise Therapeutics. The company has been striving to make breakthroughs in the field of muscle disease research, but it has faced its fair share of challenges. In fact, Edgewise recorded a cumulative net loss of $53 million during the 12-month period ending in the third quarter of 2023.
Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
